Pancreatic Cancer Research

ResearcherUniversity of BonnActive in the last 2 years

Stefan Holdenrieder

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9210-7064; OpenAlex author ID A5077502588, A5084753093. Sources: OpenAlex.

Their work

Papers
15 (first author 0, last author 7)
Trials
0
Grants
0
Labs led
2
Collaborators
26
Papers, trials and grants by year

2013: 5 papers · 2014: none · 2015: 1 paper · 2016: 3 papers · 2017: 2 papers · 2018: 1 paper · 2019: none · 2020: none · 2021: none · 2022: 1 paper · 2023: 1 paper · 2024: none · 2025: none · 2026: 1 paper

Papers 15

  1. Distinct Mutation Signatures in Peripheral Blood Mitochondrial DNA from Liquid Biopsy Reveal Insights into Pancreatic Cancer. Last author DOI 10.3390/cells15060527↗
  2. Serum biomarker panel diagnostics in pancreatic ductal adenocarcinoma: the clinical utility of soluble interleukins, IFN-γ, TNF-α and PD-1/PD-L1 in comparison … Last author DOI 10.1007/s00432-022-04112-z↗
  3. Preanalytical Variables in the Analysis of Mitochondrial DNA in Whole Blood and Plasma from Pancreatic Cancer Patients. Last author DOI 10.3390/diagnostics12081905↗
  4. Repeated mutKRAS ctDNA measurements represent a novel and promising tool for early response prediction and therapy monitoring in advanced pancreatic cancer. Last author DOI 10.1093/annonc/mdy417↗
  5. Serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death ligand 1 (sPD-L1) in advanced pancreatic cancer. Co-author DOI 10.1080/2162402x.2017.1310358↗
  6. The Impact of SMAD4 Loss on Outcome in Patients with Advanced Pancreatic Cancer Treated with Systemic Chemotherapy. Co-author DOI 10.3390/ijms18051094↗
  7. A liposomal formulation of the synthetic curcumin analog EF24 (Lipo-EF24) inhibits pancreatic cancer progression: towards future combination therapies. Co-author DOI 10.1186/s12951-016-0209-6↗
  8. Paradoxical Role of HMGB1 in Pancreatic Cancer: Tumor Suppressor or Tumor Promoter? Co-author DOI 10.21873/anticanres.10981↗
  9. Immune checkpoint therapy for pancreatic cancer. Co-author DOI 10.3748/wjg.v22.i43.9457↗
  10. Assessing novel prognostic serum biomarkers in advanced pancreatic cancer: the role of CYFRA 21-1, serum amyloid A, haptoglobin, and 25-OH vitamin D3. Co-author DOI 10.1007/s13277-014-2885-x↗
  11. Circulating nucleosomes and immunogenic cell death markers HMGB1, sRAGE and DNAse in patients with advanced pancreatic cancer undergoing chemotherapy. Last author DOI 10.1002/ijc.28294↗
  12. Prognostic value of CA 19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: results from a multicenter, pooled analys… Co-author DOI 10.1007/s00432-012-1371-3↗
  13. Cytokeratin 19-fragments (CYFRA 21-1) as a novel serum biomarker for response and survival in patients with advanced pancreatic cancer. Last author DOI 10.1038/bjc.2013.158↗
  14. Soluble receptor of advanced glycation end products (sRAGE) indicates response to chemotherapy in pancreatic cancer patients. Last author DOI 10.5414/cpp51067↗
  15. Glucose and lipid metabolism in patients with advanced pancreatic cancer receiving palliative chemotherapy. Co-author PMID 23267159↗

Closest collaborators

The 25 strongest of 26 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Michael Haas · 12 shared papers, 2013–2026 · strength 1.01
  2. Volker Heinemann · 12 shared papers, 2013–2026 · strength 1.01
  3. Stefan Hubert Boeck · 12 shared papers, 2013–2026 · strength 1.01
  4. Hannah Randeu · 2 shared papers, 2022–2026 · strength 0.42
  5. Klara Dorman · 2 shared papers, 2023–2026 · strength 0.41
  6. Steffen Ormanns · 5 shared papers, 2015–2023 · strength 0.39
  7. Stephan Krüger · 5 shared papers, 2015–2023 · strength 0.39
  8. Christoph Benedikt Westphalen · 3 shared papers, 2017–2023 · strength 0.28
  9. Monika Posaric Bauden · 2 shared papers, 2016 · strength 0.15
  10. Roland E. Andersson · 2 shared papers, 2016 · strength 0.15
  11. Daniel Ansari · 2 shared papers, 2016 · strength 0.15
  12. Michael Guenther · 1 shared paper, 2023 · strength 0.14
  13. Danmei Zhang · 1 shared paper, 2023 · strength 0.14
  14. Jens Martin Werner · 1 shared paper, 2023 · strength 0.14
  15. Lena Weiss · 1 shared paper, 2023 · strength 0.14
  16. Dominik Paul Modest · 3 shared papers, 2013–2017 · strength 0.14
  17. Christin Wittwer · 3 shared papers, 2013 · strength 0.12
  18. María José García Cebrián · 1 shared paper, 2016 · strength 0.08
  19. Henrik Johansson · 1 shared paper, 2016 · strength 0.07
  20. Martin Schlesinger · 1 shared paper, 2016 · strength 0.06
  21. Georg Feldmann · 1 shared paper, 2016 · strength 0.06
  22. Savita Bisht · 1 shared paper, 2016 · strength 0.06
  23. Marlies Michl · 1 shared paper, 2015 · strength 0.04
  24. Katharina Zeiss · 1 shared paper, 2013 · strength 0.04
  25. Frank Kullmann · 1 shared paper, 2013 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.